Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shari Damast

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Brachytherapy|December 25, 2017
Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinomaJohn M Stahl, Shari Damast, Trevor J Bledsoe, et al.
Gynecologic Oncology|August 2, 2012
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancerAna P Kiess, Shari Damast, Vicky Makker, et al.
Journal of Contemporary Brachytherapy|April 2, 2015
High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinomaShari Damast, Susan A Higgins, Elena Ratner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 27, 2015
Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristicsMelissa Rasar Young, Susan A Higgins, Elena Ratner, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2012
Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapyShari Damast, Kaled M Alektiar, Shari Goldfarb, et al.
Gynecologic Oncology|May 7, 2016
Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data BaseNataniel H Lester-Coll, Henry S Park, Charles E Rutter, et al.
International Journal of Radiation Oncology, Biology, Physics|May 16, 2025
The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated With Adjuvant Radiation Therapy: A Multi-Institutional Retrospective StudyZohaib K Sherwani, Shari Damast, Emma C Fields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2017
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario GuidelineJeanne Carter, Christina Lacchetti, Barbara L Andersen, et al.
Brachytherapy|April 15, 2026
American Brachytherapy Society Working Group Report on cancer surveillance, sexual health, and pelvic toxicity management in gynecologic malignanciesAllison Quick, Allison Garda, Amanda Rivera, et al.
Gynecologic Oncology|July 26, 2020
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort studyBritt K Erickson, Omar Najjar, Shari Damast, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Brachytherapy|December 25, 2017
Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinomaJohn M Stahl, Shari Damast, Trevor J Bledsoe, et al.
Gynecologic Oncology|August 2, 2012
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancerAna P Kiess, Shari Damast, Vicky Makker, et al.
Journal of Contemporary Brachytherapy|April 2, 2015
High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinomaShari Damast, Susan A Higgins, Elena Ratner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 27, 2015
Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristicsMelissa Rasar Young, Susan A Higgins, Elena Ratner, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2012
Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapyShari Damast, Kaled M Alektiar, Shari Goldfarb, et al.
Gynecologic Oncology|May 7, 2016
Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data BaseNataniel H Lester-Coll, Henry S Park, Charles E Rutter, et al.
International Journal of Radiation Oncology, Biology, Physics|May 16, 2025
The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated With Adjuvant Radiation Therapy: A Multi-Institutional Retrospective StudyZohaib K Sherwani, Shari Damast, Emma C Fields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2017
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario GuidelineJeanne Carter, Christina Lacchetti, Barbara L Andersen, et al.
Brachytherapy|April 15, 2026
American Brachytherapy Society Working Group Report on cancer surveillance, sexual health, and pelvic toxicity management in gynecologic malignanciesAllison Quick, Allison Garda, Amanda Rivera, et al.
Gynecologic Oncology|July 26, 2020
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort studyBritt K Erickson, Omar Najjar, Shari Damast, et al.
Pageof 6